Published in
American Association for the Advancement of Science, Science Translational Medicine, 469(10), 2018
DOI: 10.1126/scitranslmed.aat8410
Links
Tools
Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF–licensed myeloid cells
Journal article published in 2018 by
Sonia Tugues 
,
Ana Amorim ,
Sabine Spath ,
Guillaume Martin-Blondel,
Bettina Schreiner,
Donatella De Feo,
Mirjam Lutz ,
Franco Guscetti,
Petya Apostolova,
Claudia Haftmann,
Peter Hasselblatt ,
Nicolas G. Núñez,
Michael O. Hottiger ,
Maries van den Broek ,
Markus G. Manz
and other authors.
,
Ana Amorim ,
Sabine Spath ,
Guillaume Martin-Blondel,
Bettina Schreiner,
Donatella De Feo,
Mirjam Lutz ,
Franco Guscetti,
Petya Apostolova,
Claudia Haftmann,
Peter Hasselblatt ,
Nicolas G. Núñez,
Michael O. Hottiger ,
Maries van den Broek ,
Markus G. Manz
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Myeloid cells mediate GvHD immunopathology, whereas GvL relies on T cell cytotoxicity.